Company news

Annexon, Inc. news in 2024

Annexon, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)

December 15, 2024

Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in Geographic Atrophy at the Floretina-ICOOR 2024 Meeting

December 4, 2024

Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones

November 13, 2024

Annexon Biosciences to Present at the Jefferies London Healthcare Conference

November 12, 2024

Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting

October 20, 2024

Annexon to Present New Phase 2 ARCHER Data for ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting

October 14, 2024

Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in GA at the Retina Society 57th Annual Meeting and 24th Euretina Congress

September 8, 2024

Annexon Expands Senior Leadership in Commercial, Medical Affairs and Health Economics to Advance Global Late-Stage Neuroinflammatory-Targeted Portfolio

September 2, 2024

Annexon Reports Second Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones

August 11, 2024

Annexon Provides Update on ARCHER II Global Registrational Program in Geographic Atrophy

August 4, 2024

Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting

July 10, 2024

Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting

June 24, 2024

Annexon To Present Pivotal Phase 3 Data On Early And Durable Benefits With First-In-Class C1q Blocking Antibody ANX005 In Guillain-Barré Syndrome At 2024 PNS Annual Meeting

June 17, 2024

Annexon Announces Pricing of $125 Million Underwritten Public Offering

June 4, 2024

Annexon Announces Proposed Public Offering of Common Stock

June 3, 2024

Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome

June 3, 2024

Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data

June 2, 2024

Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones

May 12, 2024

Annexon Biosciences to Present at the Bank of America Health Care Conference

May 8, 2024

Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting

May 6, 2024

Annexon to Present Data Reinforcing the Neuroprotective Effects of ANX007 and C1q Inhibition in Geographic Atrophy at the ARVO 2024 Annual Meeting

April 30, 2024

Annexon Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference

April 2, 2024

Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones

March 25, 2024

Annexon Biosciences to Present at the TD Cowen 44th Annual Health Care Conference

February 26, 2024

Annexon to Host Virtual R&D Day on Guillain-Barré Syndrome, Focusing on its Serious Unmet Need and Annexon’s Novel Therapeutic Approach

February 20, 2024

Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative Diseases

January 6, 2024

Decks in 2024